Evidence map›Paper›PMID 42166100›Full record

ArticleApplied biochemistry and biotechnology2026

JARID1B-Mediated H3K4me3 Demethylation Promotes Cisplatin Resistance in Oral Squamous Cell Carcinoma Cells via the miR-495-3p/FUBP1 Axis.

Jixiong Mao, Lei Xu

Abstract read
PubMed Publisher
In one paragraph

Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jixiong MaoDepartment of Stomatology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China.
Lei XuDepartment of Oral and Maxillofacial Surgery, Central Laboratory of Jinan Stamotological Hospital, Jinan Key Laboratory of Oral Tissue Regeneration, No. 78, Wei'er Road, Shizhong District, Jinan, 250001, Shandong Province, China. xulei0517@163.com.ORCID http://orcid.org/0009-0005-7840-2047

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cisplatin (DDP) is a commonly used chemotherapeutic drug for oral squamous cell carcinoma (OSCC) clinical treatment. However, DDP resistance often brings about treatment failure. This study aims to demonstrate the mechanism of JARID1B in DDP-resistance of OSCC cells. Tissue specimens of OSCC and adjacent normal tissues were collected and OSCC cell lines resistant to DDP were established, followed by measurement of JARID1B, H3K4me3, miR-495-3p and FUBP1 levels. CCK-8 was used to detect the IC

Indexed as

Carcinoma, Squamous CellCisplatinDNA-Binding ProteinsDrug Resistance, NeoplasmHistonesJumonji Domain-Containing Histone DemethylasesMicroRNAsMouth NeoplasmsNuclear ProteinsRepressor ProteinsRNA-Binding ProteinsApoptosisCell Line, TumorCell ProliferationDemethylationHumansCisplatinDNA-Binding Proteinshistone H3 trimethyl Lys4HistonesJumonji Domain-Containing Histone DemethylasesKDM5B protein, humanMicroRNAsMIRN495 microRNA, humanNuclear ProteinsRepressor ProteinsRNA-Binding ProteinsH3K4me3JARID1BmiR-495-3pOral squamous cell carcinomaPSMD14

Identifiers

PMID42166100

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.